Basaglar KwikPen and Betrixaban Maleate

• Generic Name: insulin glargine
• Dosage Forms: injection, solution
• Other Brand Names: Basaglar KwikPen, Lantus, Lantus Solostar Pen, Toujeo SoloStar, Lantus OptiClik Cartridge, Toujeo Max SoloStar, Lantus SoloStar

Basaglar KwikPen is a long-acting insulin that starts to work several hours after injection and keeps working evenly for 24 hours.

Basaglar KwikPen is used to improve blood sugar control in adults and children with diabetes mellitus. This medicine is used to treat type 1 or type 2 diabetes in adults, and type 1 diabetes children who are at least 6 years old.

Some brands of Basaglar KwikPen are for use only in adults. Carefully follow all instructions for the brand of insulin glargine you are using.

Basaglar KwikPen may also be used for purposes not listed in this medication guide.

• Generic Name: betrixaban
• Dosage Forms: n.a.
• Other Brand Names: Bevyxxa

Prevention of venous thromboembolism in patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderately or severely restricted mobility and other risk factors for venous thromboembolism.

Pharmacologic thromboprophylaxis generally recommended in patients considered to be at high risk of venous thromboembolism. Anticoagulant prophylaxis recommended by ACCP in acutely ill, hospitalized medical patients at increased risk of thrombosis who are not actively bleeding and do not have an increased risk of bleeding. Such prophylaxis generally continued for 6–21 days until full mobility is restored or hospital discharge, whichever comes first; extended prophylaxis beyond these periods generally not recommended because of data suggesting unfavorable benefit-to-risk ratio for bleeding.

However, available data suggest benefit for extended-duration (35–42 days) betrixaban compared with standard-duration (6–14 days) enoxaparin for reducing risk of venous thromboembolism in hospitalized patients with acute medical illness and reduced mobility, at the cost of an increase in nonmajor but not major bleeding.

Safety and efficacy of betrixaban not established in patients with prosthetic heart valves.